Abstract 1486P
Background
Living with lung cancer (LC) becomes a long journey where disease consequences and treatment adverse events impact quality of life (QOL) of the patient and the caregiver. Here, HCP's and a patient organization developed and executed a personalized respiratory and physical rehabilitation pilot program for unresectable metastatic LC patients.
Methods
25 stage IV unresectable patients were recruited from a Facebook post. They received 4 physiotherapist visits, where a personalized physiotherapy program was tailored, using a personal booklet and equipment provision. All received two types of recommendations: aerobic and strength activities. The patients and caregivers also received 3 online mental support sessions. EORTC QLQ-C30 questionnaire was used at the beginning, end of the program and two months after. The physiotherapists measured the patients’ 5 repetitions sit to stand time and 10-meter walk time at the beginning and the end of the program. Significance of results was calculated with repeated measurewithin subjects T test with one way hypothesis and a confident interval of 0.95%.
Results
Significant and maintained improvement was observed in the Sit-to-stand test, from 14.9s to 12.8s, p=0.012, the 10-meter-walk test, from 0.89m/s to 1.22m/s, p=0.014, the global health status and constipation p<0.05. In addition, emotional and social functioning, fatigue symptoms and appetite loss were improved after the intervention, whereas weren't maintained two months after completion of the program. No significant change was observed in cognitive functioning, pain symptoms, dyspnea, insomnia, diarrhea and financial difficulties. Interestingly, there was high compliance from patients and caregivers to participate in the program.
Conclusions
With the limitation of low numbers of participants, our pilot program shows feasibility and efficacy of home-based rehabilitation program for LC patients. Patients’ high desire for the intervention emphasizes the unmet need. Further investigation and extended support after program completion is needed to maintain improvement.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The Israeli Lung Cancer Foundation.
Funding
The Lung Ambition Alliance.
Disclosure
S. Shilo: Financial Interests, Personal and Institutional, Advisory Board: Roche, Sanofi. D. Urban: Financial Interests, Personal, Advisory Role: Roche, Merck, Jansen, BMS, Takeda, Medison. A. Zer: Financial Interests, Personal, Invited Speaker: Roche, BMS, MSD, Takeda, Pfizer, Novartis; Financial Interests, Personal, Advisory Board: AstraZeneca, Steba, Oncohost; Financial Interests, Personal, Other, Safety Review Committee Member: Beyond Air; Financial Interests, Personal, Stocks/Shares: Nixio; Financial Interests, Institutional, Research Grant: BMS. A. Agbarya, N. Peled: Financial Interests, Personal, Advisory Role: Roche, AstraZeneca, BMS, MSD. All other authors have declared no conflicts of interest.
Resources from the same session
1199P - Developing and systematically validating homologous recombination repair gene detection method based on next-generation sequencing
Presenter: Yi Sun
Session: Poster session 10
1200P - Investigation of multiphoton microscopy as an innovative tool for intraoperative section-free histologic investigations in just a few minutes
Presenter: Martí Homs Soler
Session: Poster session 10
1201P - Novel deep learning model and validation of whole slide images in lung cancer diagnosis
Presenter: Alhassan Ahmed
Session: Poster session 10
Resources:
Abstract
1202P - A deep learning approach using routine pathology images to guide precision medicine in metastatic CRC
Presenter: Chaitanya Parmar
Session: Poster session 10
1203P - Analytical evaluation of whole genome sequencing for acute myeloid leukemia
Presenter: Guidantonio Malagoli Tagliazucchi
Session: Poster session 10
1204P - Real-world utility of whole genome sequencing for patients with cancer: Evaluation of a regional implementation of the 100,000 genomes project
Presenter: Helen Robbins
Session: Poster session 10
1205P - A retrospective machine learning-based analysis of nationwide cancer CGP data across cancer types to identify features associated with recommendation of mutation-based therapy
Presenter: Hiroaki Ikushima
Session: Poster session 10
1478P - Dual single-nucleotide polymorphism biomarker combination to select opioid for cancer pain management
Presenter: Yoshihiko Fujita
Session: Poster session 10
1479P - Use of rescue opioids and pain control after ketamine initiation in refractory cancer pain: A multicentric observational study
Presenter: Pablo Gallardo Melo
Session: Poster session 10
1480P - Long term therapy with denosumab and zoledronic acid: A comparative real-world retrospective observational study on skeletal-related events and pain in patients with metastatic breast cancer
Presenter: Giacomo Massa
Session: Poster session 10